Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study
Open Forum Infectious Diseases · 26.12.2025 · 13 (1)
DOI: 10.1093/ofid/ofaf808 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 20.01.2026. Verfasst von Aixin Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
We compared the effectiveness and safety profiles of doravirine, lamivudine, tenofovir disoproxil fumarate (DOR/3TC/TDF) with bictegravir, emtricitabine, tenofovir alafenamide fumarate (BIC/FTC/TAF) in people with HIV (PWH) who had achieved virological suppression on efavirenz (EFV)-based antiretroviral regimens.
Methods
This study was a single-center, real-world, prospective observational cohort study. The main inclusion criteria: PWH aged ≥18 years who had received an EFV-containing regimen for ≥6 months and achieved confirmed virological suppression. Participants were stratified according to clinical decisions to switch to DOR/3TC/TDF or BIC/FTC/TAF. The primary effectiveness end point was the proportion of participants with HIV-1 RNA ≥50 copies/mL at week 48, with a preset 4% noninferiority margin.
Results
A total of 349 participants received at least 1 dose of study drugs (142 in DOR group, 207 in BIC group). At 48 weeks, 2 (1.4%) in the DOR group and 1 (0.5%) in the BIC group had HIV-1 RNA ≥50 copies/mL (estimated treatment difference [ETD], 1.0%; 95% CI, −1.6% to 3.7%), establishing noninferiority. In the BIC group, mean CD4 counts decreased significantly by ∼76.5 cells/µL at week 48 (95% CI, −111.801 to −41.218; P < .001) compared with baseline. Over 48 weeks, adverse event rates were comparable between the 2 groups (P = .758). At week 48, the BIC group exhibited a baseline-adjusted mean increase of 0.269 mmol/L in total cholesterol (TC) and 0.171 mmol/L in low-density lipoprotein cholesterol (LDL-C), while the DOR group demonstrated a mean reduction of 0.453 mmol/L in triglycerides (TG), 0.412 mmol/L in TC, and 0.241 mmol/L in LDL-C relative to baseline. All β values for the group–time interaction terms were negative (P < .001). The change in body weight from baseline to week 48 in the DOR group was 1.8 kg lower than that in the BIC group (95% CI, −2.474 to −1.114; P < .001).
Conclusions
In previously virologically suppressed PWH on an EFV-based regimen, the switch to DOR/3TC/TDF maintained virological suppression noninferior to that of BIC/FTC/TAF, with favorable metabolic profiles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
- Clinical Center for HIV/AIDS, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
- Dermatology & STD Department, Chifeng Infectious Disease Prevention and Control Hospital, Inner Mongolia, Chifeng, People's Republic of China.
- Chinese Association of STD and AIDS Prevention and Control, Care and Treatment Committee, Beijing, People's Republic of China.
Zitieren
APA
Li, A., Li, Z., Li, J., Gao, Y., Dai, L., Liu, A., Zhang, H., Wang, X., Wu, L., Yao, Y., Liu, L., Ye, J., & Sun, L. (2025). Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study. Open Forum Infectious Diseases, 13(1). https://doi.org/10.1093/ofid/ofaf808
Vancouver
Li A, Li Z, Li J, Gao Y, Dai L, Liu A, et al. Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study. Open Forum Infectious Diseases. 2025;13(1). doi:10.1093/ofid/ofaf808
BibTeX
@article{Li2025,
author = {Li, Aixin and Li, Zaicun and Li, Jianwei and Gao, Yue and Dai, Lili and Liu, An and Zhang, Hongwei and Wang, Xi and Wu, Liang and Yao, Yanwei and Liu, LetiAn and Ye, Jiangzhu and Sun, Lijun},
title = {Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {13},
number = {1},
doi = {10.1093/ofid/ofaf808}
}
EUVIMED